IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer

被引:1
作者
Cui, Zhaomeng [1 ]
Liang, Huaiyu [1 ]
Luo, Rongkui [1 ]
Huang, Wen [1 ]
Yuan, Wei [1 ]
Zhang, Lei [1 ]
Luan, Lijuan [1 ]
Su, Jieakesu [1 ]
Huang, Jie [1 ]
Xu, Chen [1 ]
Hou, Yingyong [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Xiamen Branch, Dept Pathol, Xiamen 361015, Fujian, Peoples R China
关键词
IKZF3; HER2; Gastric cancer; Intestinal-type; Prognosis; GENE AMPLIFICATION; HER2; EXPRESSION; CLASSIFICATION; LAPATINIB; RARE;
D O I
10.1007/s00432-024-05868-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored. Methods We examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays. Results IKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.54%, 24/208). Co-amplification of IKZF3 and HER2 was detected in 8.16% (16/196) of IGC patients and in 2.40% (5/208) of other types. IKZF3 amplification showed significant correlation with IGC (P = 0.001) and HER2 amplification (P = 0.0001). IKZF3 amplification exhibited significantly worse disease-free survival (DFS) (P = 0.014) and overall survival (OS) (P = 0.018) in GC patients, particularly in IGC (DFS: P < 0.001; OS: P < 0.001), rather than other types. Cox regression analysis demonstrate IKZF3 amplification as an independent poor prognostic factor in all GCs (P = 0.006, P = 0.004 respectively) and in IGC patients, regardless of stages I-II or III-IV (P = 0.007, P = 0.004 respectively). On the other hand, HER2 amplification was significantly associated with worse DFS (P = 0.008) and OS (P = 0.01) in IGC patients, but not in all GCs and in multivariate analysis. Within the subset of patients with HER2 amplification, those also exhibiting IKZF3 amplification displayed potential poorer prognosis (P = 0.08, P = 0.11 respectively). Conclusion IKZF3 amplification was detected in minority of GC patients, especially in IGC, and was an independent indicator of poor prognosis. Our study, for the first time, found the prognostic value of IKZF3 was superior to HER2 for GC patients.
引用
收藏
页数:13
相关论文
共 39 条
[1]   Gene amplification in cancer [J].
Albertson, Donna G. .
TRENDS IN GENETICS, 2006, 22 (08) :447-455
[2]   The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma [J].
Awwad, Mohamed H. S. ;
Kriegsmann, Katharina ;
Plaumann, Julian ;
Benn, Michael ;
Hillengass, Jens ;
Raab, Marc S. ;
Bertsch, Uta ;
Munder, Markus ;
Weisel, Katja ;
Salwender, Hans Juergen ;
Haenel, Mathias ;
Fenk, Roland ;
Duerig, Jan ;
Mueller-Tidow, Carsten ;
Goldschmidt, Hartmut ;
Hundemer, Michael .
ONCOIMMUNOLOGY, 2018, 7 (10)
[3]   HER2 Amplification in p53-Mutated Endometrial Carcinomas [J].
Balestra, Ambre ;
Larsimont, Denis ;
Noel, Jean-Christophe .
CANCERS, 2023, 15 (05)
[4]   HER2-positive gastric cancer [J].
Boku, Narikazu .
GASTRIC CANCER, 2014, 17 (01) :1-12
[5]   Clinicopathological Variation of Lauren Classification in Gastric Cancer [J].
Chen, Yun-Chi ;
Fang, Wen-Liang ;
Wang, Ruei-Fang ;
Liu, Chien-An ;
Yang, Muh-Hwa ;
Lo, Shu-Shun ;
Wu, Chew-Wen ;
Li, Anna Fen-Yau ;
Shyr, Yi-Ming ;
Huang, Kuo-Hung .
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (01) :197-202
[6]  
Chia NY, 2016, Annals of Oncology Advance Access, V4, P1
[7]   Her2 Amplification in Gastric Cancer Is a Rare Event Restricted to the Intestinal Phenotype [J].
Cruz-Reyes, Carolina ;
Gamboa-Dominguez, Armando .
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2013, 21 (03) :240-246
[8]   HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series [J].
Grabsch, Heike ;
Sivakumar, Shivan ;
Gray, Sally ;
Gabbert, Helmut E. ;
Mueller, Wolfram .
CELLULAR ONCOLOGY, 2010, 32 (1-2) :57-65
[9]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[10]   The Ikaros family in lymphocyte development [J].
Heizmann, Beate ;
Kastner, Philippe ;
Chan, Susan .
CURRENT OPINION IN IMMUNOLOGY, 2018, 51 :14-23